BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu CH, Lu CH, Wong SH, Lin LT. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. Front Immunol 2020;11:616595. [PMID: 33613542 DOI: 10.3389/fimmu.2020.616595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Dini Fatini Mohammad Faizal N, Cairul Iqbal Mohd Amin M. Recent updates on liposomal formulations for detection, prevention and treatment of coronavirus disease (COVID-19). Int J Pharm 2023;630:122421. [PMID: 36410670 DOI: 10.1016/j.ijpharm.2022.122421] [Reference Citation Analysis]
2 Kilcoyne A, Jordan E, Thomas K, Pepper AN, Zhou A, Chappell D, Amarapala M, Thériault R, Thompson M. Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England. CEOR 2022;Volume 14:231-47. [DOI: 10.2147/ceor.s360741] [Reference Citation Analysis]
3 Negru PA, Radu AF, Vesa CM, Behl T, Abdel-Daim MM, Nechifor AC, Endres L, Stoicescu M, Pasca B, Tit DM, Bungau SG. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir. Biomed Pharmacother 2022;147:112700. [PMID: 35131656 DOI: 10.1016/j.biopha.2022.112700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Kilcoyne A, Jordan E, Thomas K, Pepper AN, Zhou A, Chappell D, Amarapala M, Thériault R, Thompson M. Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with Coronavirus Disease 19 (COVID-19) from the perspective of National Health Service England.. [DOI: 10.1101/2022.02.11.22270859] [Reference Citation Analysis]
5 Miguez-Rey E, Choi D, Kim S, Yoon S, Săndulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin Investig Drugs 2022;:1-18. [PMID: 35164631 DOI: 10.1080/13543784.2022.2030310] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
6 Kilcoyne A, Jordan E, Zhou A, Thomas K, Pepper AN, Chappell D, Amarapala M, Hughes A, Thompson M. Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective. J Med Econ 2022;:1-21. [PMID: 35037816 DOI: 10.1080/13696998.2022.2030148] [Reference Citation Analysis]
7 Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci Alliance 2022;5:e202101200. [PMID: 35012962 DOI: 10.26508/lsa.202101200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
8 Liu CH, Lu CH, Lin LT. Pandemic Strategies with Computational and Structural Biology against COVID-19: A Retrospective. Comput Struct Biotechnol J 2021. [PMID: 34900126 DOI: 10.1016/j.csbj.2021.11.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Al-Karmalawy AA, Soltane R, Abo Elmaaty A, Tantawy MA, Antar SA, Yahya G, Chrouda A, Pashameah RA, Mustafa M, Abu Mraheil M, Mostafa A. Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. Vaccines (Basel) 2021;9:1317. [PMID: 34835248 DOI: 10.3390/vaccines9111317] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
10 Kilcoyne A, Jordan E, Zhou A, Thomas K, Pepper AN, Chappell D, Amarapala M, Hughes A, Thompson M. Clinical Benefits and Budget Impact of Lenzilumab plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with COVID-19 in the United States from the Hospital Perspective.. [DOI: 10.1101/2021.10.06.21264651] [Reference Citation Analysis]
11 Rani J, Bhargav A, Khan FI, Ramachandran S, Lai D, Bajpai U. In silico prediction of natural compounds as potential multi-target inhibitors of structural proteins of SARS-CoV-2. J Biomol Struct Dyn 2022;40:12118-34. [PMID: 34486935 DOI: 10.1080/07391102.2021.1968497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR. Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein. J Med Chem 2021. [PMID: 34328726 DOI: 10.1021/acs.jmedchem.1c00477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]